TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05098132: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 364 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT05098132 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05098132 Rescue Dossier →